Akums Q4 revenue climbs to Rs. 1,158 crore; PAT surges 135%

FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies

Akums posts strong FY26 performance as EBITDA surges 61.6% in Q4

Artemis Medicare Q4 FY26 revenue rises 16.4% to Rs. 27,923 lakh, net profit jumps 32.1%

The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies

Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore

The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year

Biocon posts strong Q3FY26 growth, boosted by biosimilars & generics

Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore

Integris Medtech files DRHP with SEBI for IPO

The company plans to use the funds raised from the net proceeds to repay or prepay certain loans

Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr

Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore

Marksans Pharma FY25 PAT up 21% at Rs. 382.6 Cr

Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24

Biocon posts Q3 FY25 PAT at Rs. 25 Cr

The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars

Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore